Prelude Therapeutics (PRLD) Free Cash Flow (2019 - 2026)

Prelude Therapeutics has disclosed Free Cash Flow across 8 years of filings, most recently posting -$21.7 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$21.7 million, up 36.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$43.8 million (up 58.35% YoY), and the FY2025 annual result was -$56.4 million, up 45.22% from the prior year.
• Free Cash Flow came in at -$21.7 million for Q1 2026 at Prelude Therapeutics, down from $23.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $23.1 million in Q4 2025 to a low of -$34.3 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$23.4 million (2024), against an average of -$22.1 million.
• Across the five-year window, Free Cash Flow tumbled 44.53% in 2023 and soared 215.35% in 2025, its largest moves.
• Prelude Therapeutics' Free Cash Flow stood at -$20.4 million in 2022, then decreased by 21.17% to -$24.7 million in 2023, then rose by 18.88% to -$20.0 million in 2024, then jumped by 215.35% to $23.1 million in 2025, then sank by 193.8% to -$21.7 million in 2026.
• The last three Free Cash Flow figures came in at -$21.7 million (Q1 2026), $23.1 million (Q4 2025), and -$19.1 million (Q3 2025), per Business Quant data.